

JUL 10 2009

Application No. 10/549,893  
Amendment dated: July 10, 2009

2

Docket No.: 68115(46590)

**AMENDMENTS TO THE CLAIMS**

Applicants respectfully request that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

1 - 22. (canceled)

23. (currently amended) A controlled release composition for oral administration, wherein

(A) a core containing (1) (+)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide or a salt thereof, and (2) a hydrophilic polymer selected from hydroxypropylcellulose, and low-substituted hydroxypropylcellulose, wherein an inert carrier particle is coated with a coating layer comprising (1) (+)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide or a salt thereof, and (2) a hydrophilic polymer selected from hydroxypropylcellulose, and low-substituted hydroxypropylcellulose, which is coated with

(B) a coating layer containing (1) methacrylic acid copolymers as an enteric coating agent, (2) talc as a lubricant, and (3) a plasticizer selected from polyethylene glycol and triethyl citrate, wherein the core is in a granule form having the average particle diameter of from about 50 to about 2000  $\mu\text{m}$ .

24 - 26. (canceled)

27. (previously amended) The controlled release composition according to claim 23, which is used for prevention or treatment of prostate cancer or breast cancer.

28 - 35. (canceled)

BOS2 745868 1